Erstellt von fchar99
Arrowhead Pharmaceuticals Inc. diskutieren
Arrowhead Pharmaceuticals Inc.
WKN: A2AGYB / Symbol: ARWR / Name: Arrowhead Pharma / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
26,68 €
-0,45 %
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock, down previously from $90.00.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals Inc. is a biotechnology company pioneering RNA interference (RNAi) technology to treat diseases by silencing specific genes. This innovative approach holds promise for conditions like liver diseases and rare genetic disorders. The company boasts a strong pipeline and strategic partnerships with industry giants such as Amgen and Janssen. Recent clinical successes have boosted investor confidence, indicating significant market potential. Honista APK users might find Arrowhead's advancements and stock movements particularly relevant for investment opportunities.
Neueste Beiträge
TD_Cowen in Humana Inc. diskutieren